<?xml version='1.0' encoding='utf-8'?>
<document id="25313206"><sentence text="Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor."><entity charOffset="0-17" id="DDI-PubMed.25313206.s1.e0" text="Carboxymefloquine" /><entity charOffset="65-75" id="DDI-PubMed.25313206.s1.e1" text="mefloquine" /><pair ddi="false" e1="DDI-PubMed.25313206.s1.e0" e2="DDI-PubMed.25313206.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25313206.s1.e0" e2="DDI-PubMed.25313206.s1.e1" /></sentence><sentence text="Malaria patients are frequently coinfected with HIV and mycobacteria causing tuberculosis, which increases the use of coadministered drugs and thereby enhances the risk of pharmacokinetic drug-drug interactions" /><sentence text=" Activation of the pregnane X receptor (PXR) by xenobiotics, which include many drugs, induces drug metabolism and transport, thereby resulting in possible attenuation or loss of the therapeutic responses to the drugs being coadministered" /><sentence text=" While several artemisinin-type antimalarial drugs have been shown to activate PXR, data on nonartemisinin-type antimalarials are still missing"><entity charOffset="15-26" id="DDI-PubMed.25313206.s4.e0" text="artemisinin" /><entity charOffset="92-106" id="DDI-PubMed.25313206.s4.e1" text="nonartemisinin" /><pair ddi="false" e1="DDI-PubMed.25313206.s4.e0" e2="DDI-PubMed.25313206.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25313206.s4.e0" e2="DDI-PubMed.25313206.s4.e1" /></sentence><sentence text=" Therefore, this study aimed to elucidate the potential of nonartemisinin antimalarial drugs and drug metabolites to activate PXR"><entity charOffset="59-73" id="DDI-PubMed.25313206.s5.e0" text="nonartemisinin" /></sentence><sentence text=" We screened 16 clinically used antimalarial drugs and six major drug metabolites for binding to PXR using the two-hybrid PXR ligand binding domain assembly assay; this identified carboxymefloquine, the major and pharmacologically inactive metabolite of the antimalarial drug mefloquine, as a potential PXR ligand"><entity charOffset="180-197" id="DDI-PubMed.25313206.s6.e0" text="carboxymefloquine" /><entity charOffset="276-286" id="DDI-PubMed.25313206.s6.e1" text="mefloquine" /><pair ddi="false" e1="DDI-PubMed.25313206.s6.e0" e2="DDI-PubMed.25313206.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25313206.s6.e0" e2="DDI-PubMed.25313206.s6.e1" /></sentence><sentence text=" Two-hybrid PXR-coactivator and -corepressor interaction assays and PXR-dependent promoter reporter gene assays confirmed carboxymefloquine to be a novel PXR agonist which specifically activated the human receptor"><entity charOffset="122-139" id="DDI-PubMed.25313206.s7.e0" text="carboxymefloquine" /></sentence><sentence text=" In the PXR-expressing intestinal LS174T cells and in primary human hepatocytes, carboxymefloquine induced the expression of drug-metabolizing enzymes and transporters on the mRNA and protein levels"><entity charOffset="81-98" id="DDI-PubMed.25313206.s8.e0" text="carboxymefloquine" /></sentence><sentence text=" The crucial role of PXR for the carboxymefloquine-dependent induction of gene expression was confirmed by small interfering RNA (siRNA)-mediated knockdown of the receptor"><entity charOffset="33-50" id="DDI-PubMed.25313206.s9.e0" text="carboxymefloquine" /></sentence><sentence text=" Thus, the clinical use of mefloquine may result in pharmacokinetic drug-drug interactions by means of its metabolite carboxymefloquine"><entity charOffset="27-37" id="DDI-PubMed.25313206.s10.e0" text="mefloquine" /><entity charOffset="118-135" id="DDI-PubMed.25313206.s10.e1" text="carboxymefloquine" /><pair ddi="false" e1="DDI-PubMed.25313206.s10.e0" e2="DDI-PubMed.25313206.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25313206.s10.e0" e2="DDI-PubMed.25313206.s10.e1" /></sentence><sentence text=" Whether these in vitro findings are of in vivo relevance has to be addressed in future clinical drug-drug interaction studies" /><sentence text=" " /></document>